Leading Brands

Brand building is at the core of our marketing strategy. A significant proportion of our revenues is derived from brands which are among top 10 in their respective subgroups. We derive a higher proportion of our revenues from our top 10 and top 25 mother brand groups, as compared to the average of the top 25 players in the IPM

  Top 10 Mother Brand Groups Revenue Contribution Top 25 Mother Brand Groups Revenue Contribution
Eris Lifesciences 72.5% 92.2%
Average of Top 25 Companies in IPM 48.0% 69.2%

Source: IMS TSA MAT, March 2017

Top Ten Brands

Brand Year of launch Indication Subgroup(including combinations) Sales Value in INR Millions Brand CAGR (FY 13-17) Market CAGR (FY 13-17) Prescription rank
Glimisave 2007 Anti – Diabetes Glimepiride 1,708.8 29.0% 18.6% 3
Eritel 2008 Hypertension Telmisartan 1,022.2 28.5% 21.1% 4
Rabonik 2008 Gastroenterology Rabeprazole 541.8 9.2% 14.4% 10
Remylin 2007 Diabetic Neuropathy Mecobalamin+Colecalciferol 529.7 10.2% 13.7% 8
Tayo 2011 Vit. D deficiency in Metabolic disorders Vitamin D 526.7 7.7% 23.4% 5
Olmin 2010 Hypertension Olmesartan 487.1 36.1% 19.2% 3
Atorsave 2007 Lipid Lowering Atorvastatin 377.3 7.2% 2.0% 6
LnBloc 2012 Hypertension Cilnidipine 359.9 168.4% 75.7% 2
Tendia 2015 Anti – diabetes Teneligliptin 287.8 448.3%* 352.4%* 3
Crevast 2010 Lipid Lowering Rosuvastatin 229.6 20.4% 23.2% 6

Source: IMS TSA and Medical Audit MAT, Mar 2017
*Growth over FY 16 as brand launched post 2013